Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Does n-3 LCPUFA supplementation during pregnancy increase the IQ of children at school age? Follow-up of a randomised controlled trial
Author: Gould, J.
Treyvaud, K.
Yelland, L.
Anderson, P.
Smithers, L.
Gibson, R.
McPhee, A.
Makrides, M.
Citation: BMJ Open, 2016; 6(5):e011465-1-e011465-9
Publisher: BMJ Publishing Group Ltd.
Issue Date: 2016
ISSN: 2044-6055
Statement of
Jacqueline F Gould, Karli Treyvaud, Lisa N Yelland, Peter J Anderson, Lisa G Smithers, Robert A Gibson, Andrew J McPhee, Maria Makrides
Abstract: Introduction Despite recommendations that pregnant women increase their docosahexaenoic acid (DHA) intake to support fetal brain development, a recent systematic review found a lack of high-quality data to support the long-term effects of DHA supplementation on children's neurodevelopment. Methods and analysis We will assess child neurodevelopment at 7 years of age in follow-up of a multicentre double-blind randomised controlled trial of DHA supplementation in pregnancy. In 2010–2012, n=2399 Australian women with a singleton pregnancy <21 weeks’ gestation were randomised to receive 3 capsules daily containing a total dose of 800 mg DHA/day or a vegetable oil placebo until birth. N=726 children from Adelaide (all n=97 born preterm, random sample of n=630 born at term) were selected for neurodevelopmental follow-up and n=638 (preterm n=85) are still enrolled at 7 years of age. At the 7-year follow-up, a psychologist will assess the primary outcome, IQ, with the Wechsler Abbreviated Scale of Intelligence, Second Edition. Specific measures of executive functioning (Fruit Stroop and the Rey Complex Figure), attention (Test of Everyday Attention for Children), memory and learning (Rey Auditory Verbal Learning Test), language (Clinical Evaluation of Language Fundamentals, Fourth Edition) and basic educational skills (Wide Range Achievement Test, Fourth Edition) will also be administered. Caregivers will be asked to complete questionnaires measuring behaviour and executive functioning. Families, clinicians and research personnel are blinded to group assignment with the exception of families who requested unblinding prior to the follow-up. All analyses will be conducted according to the intention-to-treat principal. Ethics and dissemination All procedures will be approved by the relevant institutional ethics committees prior to start of the study. The results of this study will be disseminated in peer-reviewed journal publications and academic presentations. Trial registration numbers ACTRN12605000569606 and ACTRN12614000770662.
Keywords: Humans; Prenatal Exposure Delayed Effects; Docosahexaenoic Acids; Prenatal Care; Administration, Oral; Follow-Up Studies; Double-Blind Method; Child Development; Intelligence; Learning; Pregnancy; Dietary Supplements; Adult; Child; Infant, Newborn; Pregnant Women; Australia; Female
Rights: © By the authors. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://
RMID: 0030047988
DOI: 10.1136/bmjopen-2016-011465
Appears in Collections:Psychology publications

Files in This Item:
File Description SizeFormat 
hdl_102826.pdfPublished Version1.27 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.